Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
October 17, 2024 07:15 ET
|
Appili Therapeutics Inc.
ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy ...
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
March 12, 2024 07:12 ET
|
Appili Therapeutics Inc.
HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 21, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Global Biodefense Market Revenue Will Attain US$24.5 Bn by the End of 2030, Forecasts Fairfield Market Research in a New Report
April 27, 2023 12:56 ET
|
Fairfield Consultancy Services OPC Pvt Ltd
London, April 27, 2023 (GLOBE NEWSWIRE) -- Projected to demonstrate a healthy CAGR of 6.3% between 2023 and 2030, the global biodefense market valuation is expected to reach US$24.5 Bn by the end of...
Biodefense Market Sales are Estimated to Cross US$ 32.99 billion by 2033, Rise in Sales for Vaccines Surges the Demand for Biodefense | Future Market Insights, Inc.
February 15, 2023 19:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
DUBAI, United Arab Emirates, Feb. 15, 2023 (GLOBE NEWSWIRE) -- It is estimated that the Biodefense Market is anticipated to reach US$ 32.99 billion by 2033 after being valued at US$ 16.31 billion in...
Biodefense Market Value Anticipated To Reach US$ 19.1 Billion By 2027: Acumen Research And Consulting
March 31, 2021 13:06 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Biodefense Market– Global Industry Analysis, Market Size, Opportunities and...
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine
January 07, 2021 06:00 ET
|
CytoDel Inc
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection Supports the Development of New Approaches to...
Biodefense Market by Type and Application - Global Industry Analysis and Forecast To 2022
November 21, 2017 06:49 ET
|
Crystal Market Research
LAS VEGAS, Nov. 21, 2017 (GLOBE NEWSWIRE) -- The latest trending report published by Crystal Market Research titled, Biodefense Market, approximates that the Biodefense Market size is estimated to...
PositiveID Corporation Announces 2015 Highlights and 2016 Outlook
January 11, 2016 08:30 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., Jan. 11, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today...
PositiveID Corporation to Present at the SeeThruEquity Microcap Healthcare Investor Conference on January 11, 2016
January 05, 2016 08:30 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., Jan. 05, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences tools and diagnostics company, announced today that its...